2. Academic Validation
  3. TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease

TL1A: A New Potential Target in the Treatment of Inflammatory Bowel Disease

  • Curr Drug Targets. 2021;22(7):760-769. doi: 10.2174/1389450122999210120205607.
Federica Furfaro 1,  Ludovico Alfarone 1,  Daniela Gilardi 1,  Carmen Correale 1,  Mariangela Allocca 1,  Gionata Fiorino 1,  Marjorie Argollo 2,  Alessandra Zilli 1,  Eirini Zacharopoulou 1,  Laura Loy 1,  Giulia Roda 1,  Silvio Danese 1
Affiliations

Affiliations

  • 1 Humanitas Clinical and Research Center - IRCCS -, via Manzoni 56, 20089 Rozzano (Mi), Italy.
  • 2 IBD Unit Universidade Federal de Sao Paulo, Sao Paulo, Brazil.
PMID: 33475057 DOI: 10.2174/1389450122999210120205607
Abstract

Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), are chronic inflammatory diseases of the gastrointestinal tract. In the last few years, the development of biological agents targeting cytokines and receptors involved in IBD pathogenesis has led to better outcomes and has improved the course of the disease. Despite their effectiveness, drugs such as tumor necrosis factor (TNF) inhibitors, anti-Interleukin-12/23 and anti-integrins, do not induce a response in about one-third of patients, and 40% of patients lose response over time. Therefore, more efficient therapies are required. Recent studies showed that TL1A (Tumor necrosis factor-like cytokine 1A) acts as a regulator of mucosal immunity and participates in immunological pathways involved in the IBD pathogenesis. In this review article, we analyze the role of TL1A as a new potential target therapy in IBD patients.

Keywords

Crohn's disease; DR3; Inflammatory Bowel Diseases; TL1A; Ulcerative colitis; anti-TL1A; fibrosis; inflammation; mucosal immune system.

Figures
Products